Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGAV | P06756 | 2/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7173937 | 0.99 | GPR139 (0.45) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL24036947 | 0.88 | L3MBTL1 (0.40) | ROCK2ROCK1 | |
| SCHEMBL7357336 | 0.88 | ITGB3 (0.53) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL7171364 | 0.86 | ALDH1A1 (0.46) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL25625540 | 0.85 | PNMT (0.46) | GPR139 | |
| SCHEMBL24036821 | 0.84 | ITGB1 (0.40) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL24036824 | 0.84 | ITGB3 (0.40) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL25625472 | 0.84 | ITGB1 (0.40) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL24036950 | 0.83 | TACR3 (0.39) | ROCK2ROCK1 | |
| SCHEMBL24036750 | 0.82 | GPR139 (0.50) | GPR139ITGB3ITGAVITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | GPR139 676/4885ITGB3 4177/4885ITGAV 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.